Loading provider…
Loading provider…
Dermatology Physician in Boston, MA
NPI: 1154383610Primary Practice Location
TUFTS MEDICAL CENTER
755 Washington St, Boston, MA
Primary Employer
Pratt Associates
tuftsmedicine.org
HQ Phone
Get MD Jeffrey's Phone Numberphone_androidMobile
Get MD Jeffrey's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License

American Board of Dermatology
Dermatology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 875 | 1,223 |
| 2 | 17000Destruction of skin growth | 596 | 836 |
| 3 | 17003Destruction of 2-14 skin growths | 475 | 3,238 |
| 4 | 17110Destruction of up to 14 skin growths | 313 | 389 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 232 | 334 |
Authors: Sikora, Brooke C, Sobell, Jeffrey M
Journal: Semin Cutan Med Surg
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.
Authors: Mark Lebwohl, Thomas Scharnitz, Joseph Merola, Howard Sofen, John Osborne
Journal: Dermatol Ther (Heidelb)
Publication Date: 2025-02-07
Using targeted therapies for inflammatory dermatoses.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Semin Cutan Med Surg
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Mirikizumab, DRUG: Secukinumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Mirikizumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Mirikizumab